ADMA Biologics, Inc. (NASDAQ:ADMA) Position Boosted by Cubist Systematic Strategies LLC

Cubist Systematic Strategies LLC raised its holdings in shares of ADMA Biologics, Inc. (NASDAQ:ADMA) by 3,269.1% during the 4th quarter, Holdings Channel reports. The fund owned 384,076 shares of the biotechnology company’s stock after purchasing an additional 372,676 shares during the period. Cubist Systematic Strategies LLC’s holdings in ADMA Biologics were worth $6,587,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently added to or reduced their stakes in the company. GAMMA Investing LLC raised its stake in shares of ADMA Biologics by 106.6% during the fourth quarter. GAMMA Investing LLC now owns 1,874 shares of the biotechnology company’s stock valued at $32,000 after purchasing an additional 967 shares in the last quarter. Mark Sheptoff Financial Planning LLC acquired a new stake in shares of ADMA Biologics in the 4th quarter worth approximately $35,000. Vision Financial Markets LLC bought a new position in shares of ADMA Biologics in the fourth quarter valued at approximately $51,000. AlphaQuest LLC acquired a new position in shares of ADMA Biologics during the fourth quarter valued at approximately $84,000. Finally, CIBC Private Wealth Group LLC raised its holdings in ADMA Biologics by 137.1% during the fourth quarter. CIBC Private Wealth Group LLC now owns 5,108 shares of the biotechnology company’s stock worth $95,000 after purchasing an additional 2,954 shares in the last quarter. Institutional investors and hedge funds own 75.68% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently commented on ADMA shares. Cantor Fitzgerald reissued an “overweight” rating and issued a $25.00 price objective on shares of ADMA Biologics in a research note on Tuesday, March 4th. Raymond James boosted their price target on shares of ADMA Biologics from $25.00 to $32.00 and gave the stock a “strong-buy” rating in a research report on Thursday.

ADMA Biologics Stock Down 10.2 %

Shares of ADMA Biologics stock opened at $21.20 on Friday. ADMA Biologics, Inc. has a 12-month low of $6.84 and a 12-month high of $25.67. The firm has a market capitalization of $5.04 billion, a PE ratio of 75.71 and a beta of 0.57. The company has a quick ratio of 3.26, a current ratio of 7.09 and a debt-to-equity ratio of 0.48. The stock’s fifty day moving average is $20.17 and its 200-day moving average is $18.69.

ADMA Biologics (NASDAQ:ADMA) last posted its quarterly earnings data on Wednesday, May 7th. The biotechnology company reported $0.14 EPS for the quarter, missing analysts’ consensus estimates of $0.16 by ($0.02). ADMA Biologics had a net margin of 17.80% and a return on equity of 53.20%. The firm had revenue of $114.80 million for the quarter, compared to analysts’ expectations of $116.40 million. During the same period in the prior year, the company posted $0.08 earnings per share. ADMA Biologics’s quarterly revenue was up 40.2% compared to the same quarter last year. Equities analysts anticipate that ADMA Biologics, Inc. will post 0.51 earnings per share for the current year.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.